Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7452104 | 0.88 | NPSR1 (0.68) | NPSR1LMNAKDM4EALDH1A1POLB | |
| SCHEMBL7416729 | 0.85 | NPSR1 (0.64) | NPSR1LMNAKDM4EALDH1A1POLB | |
| SCHEMBL7458560 | 0.85 | NPSR1 (0.64) | NPSR1LMNAKDM4EALDH1A1POLB | |
| SCHEMBL7459195 | 0.85 | NPSR1 (0.75) | NPSR1LMNAKDM4EALDH1A1POLB | |
| SCHEMBL4931496 | 0.83 | NPSR1 (0.62) | NPSR1LMNAKDM4EALDH1A1POLB | |
| SCHEMBL7459875 | 0.82 | NPSR1 (0.61) | NPSR1LMNAKDM4EALDH1A1POLB | |
| SCHEMBL7463997 | 0.82 | NPSR1 (0.61) | NPSR1LMNAKDM4EALDH1A1POLB | |
| SCHEMBL7459881 | 0.82 | NPSR1 (0.61) | NPSR1LMNAKDM4EALDH1A1POLB | |
| SCHEMBL7416513 | 0.81 | NPSR1 (0.60) | NPSR1LMNAKDM4EALDH1A1POLB | |
| SCHEMBL7414060 | 0.80 | NPSR1 (0.59) | NPSR1LMNAKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-0937072-B1 | THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABA A alpha5 RECEPTOR SUBTYPE | MERCK SHARP & DOHME (GB) | 2002-01-09 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| US-6262103-B1 | ALZHEIMER'S DISEASE. | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-17 | — | — | US | disclosed |
| US-6156787-A | Substituted thienlycyclohexanone derivatives for enhancing cognition | MERCK SHARP & DOHME LIMITED (GB) | 2000-12-05 | — | — | US | disclosed |
| US-6143773-A | Substituted thienobenzisoxazole derivatives for enhancing cognition | MERCK SHARP & DOHME LIMITED (GB) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | NPSR1 405/4885LMNA 2245/4885KDM4E 3000/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | NPSR1 405/4885LMNA 2245/4885KDM4E 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.